



NATIONAL INSTITUTE
FOR INDUSTRIAL
PROPERTY

PATENT OF INVENTION

UTILITY CERTIFICATE - CERTIFICATE OF ADDITION

OFFICIAL COPY

The Director General of the National Institute for Industrial Property certifies that the attached document is the true certified copy of an application for an Industrial Property Right filed at the Institute.

Issued in Paris, 14 DEC. 2004

For the Director General of the
National Institute for Industrial Property,
The Head of the Patents Division

(signature)

Martine PLANCHE

NATIONAL
INSTITUTE FOR
INDUSTRIAL
PROPERTY

NATIONAL PUBLIC INSTITUTION
DB 267/220104

HEAD OFFICE

26 bis, rue de Saint-Petersbourg
75800 PARIS cedex 08
Telephone: 33 (0)1 53 04 53 04
Facsimile: 33 (0)1 53 04 45 23
www.inpi.fr

CREATED BY LAW NO. 51-444 OF 19th APRIL 1951

INPI

NATIONAL
INSTITUTE FOR
INDUSTRIAL PROPERTY

26bis, rue de Saint Pétersbourg - 75800 Paris Cedex 08
For information: INPI DIRECT

Single-rate tel. no. 0 825 83 85 87
0.15 € /min inc. all taxes

Facsimile: 33 (0)1 53 04 52 65

**PATENT OF INVENTION
UTILITY CERTIFICATE**
Intellectual Property Code - Book VI

cerfa
No. 11354*04

PA1

REQUEST FOR GRANT

page 1/2

Reserved for INPI

This form is to be completed legibly in black ink DB 540 @ W /030103

DEPOSITION OF DOCUMENTS DATE 31 MARCH 2004 PLACE 75 INPI PARIS 26Bis SP NATIONAL REGISTRATION NO. GIVEN BY THE INPI 0403359 FILING DATE GIVEN BY THE INPI 31 MARCH 2004		1 NAME AND ADDRESS OF THE APPLICANT OR OF THE AUTHORISED AGENT TO WHOM CORRESPONDENCE MUST BE ADDRESSED LES LABORATOIRES SERVIER Direction Brevets 12, Place de la Défense 92415 COURBEVOIE Cedex FRANCE	
Your references for this file (optional) 71084-OX			
Confirmation of deposit by facsimile		<input type="checkbox"/> No. given by INPI to the facsimile	
2 NATURE OF THE APPLICATION		Mark one of the following 4 boxes	
Patent application		<input checked="" type="checkbox"/>	
Application for a Utility Certificate		<input type="checkbox"/>	
Divisional application		<input type="checkbox"/>	
<i>Initial patent application</i>		No.	Date
<i>or initial utility certificate application</i>		No.	Date
Conversion of a European Patent Application		<input type="checkbox"/>	
<i>Initial patent application</i>		No.	Date
3 TITLE OF THE INVENTION (maximum 200 characters or spaces) NEW ASSOCIATION BETWEEN A HETEROCYCLIC COMPOUND AND AN ANTIOXIDANT AGENT, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM			
4 DECLARATION OF PRIORITY OR REQUEST FOR THE BENEFIT OF THE FILING DATE OF A PRIOR FRENCH APPLICATION		Country or organisation Date No. Country or organisation Date No. Country or organisation Date No. <input type="checkbox"/> If there are other priorities, mark the box and use the "Continuation" form	
5 APPLICANT (Mark one of the 2 boxes)		<input checked="" type="checkbox"/> Legal person <input type="checkbox"/> Natural person	
Surname or company name		LES LABORATOIRES SERVIER	
Forenames			
Legal nature			
SIREN No.			
APE-NAF Code			
Domicile or registered office	Street	12, Place de la Défense	
	Postal code and town	9 2 4 1 5 COURBEVOIE Cedex	
	Country	FRANCE	
Nationality		FRENCH	
Telephone no. (optional)		01.55.72.60.00 Facsimile no. (optional) 01.55.72.72.13	
E-mail address (optional)			
		<input checked="" type="checkbox"/> If there is more than one Applicant, mark the box and use the "Continuation" form	

Completion of Page 2 is obligatory.

INPINATIONAL
INSTITUTE FOR
INDUSTRIAL PROPERTY**PATENT OF INVENTION
UTILITY CERTIFICATE****REQUEST FOR GRANT**
page 2/2**PA2**

Reserved for INPI

DEPOSITION OF DOCUMENTS DATE 31 MARCH 2004 PLACE 75 INPI PARIS 26Bis SP NATIONAL REGISTRATION NO. GIVEN BY THE INPI 0403359		DB 540 W /191203
6 AUTHORISED AGENT <i>(where applicable)</i>		
Surname		KUEHM-CAUBERE
Forename		Catherine
Practice or company		LES LABORATOIRES SERVIER
Nationality		
No. of standing power of attorney and/or of contractual bond		
Address	Street	12, Place de la Défense
	Postal code and town	9 2 4 1 5 COURBEVOIE Cedex
	Country	FRANCE
Telephone no. (optional)		01.55.72.60.00
Facsimile no. (optional)		01.55.72.72.13
E-mail address (optional)		
7 INVENTOR(S)		
The inventors are necessarily natural persons.		
The Applicants and the inventors are the same		<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No : In this case, complete the "Declaration of Inventorship" form
8 SEARCH REPORT		
immediate drawing up or deferred drawing up		<input checked="" type="checkbox"/> <input type="checkbox"/> Selection must be made on filing (cf. Explanatory Notice Section 8)
9 REDUCTION IN FEES		
For natural persons only <input type="checkbox"/> Requested for the first time for this invention (attach a notice of non-imposition) <input type="checkbox"/> Obtained prior to this deposit for this invention (attach a copy of the admissibility decision for fee waiver or indicate its reference): FA		
10 NUCLEOTIDE AND/OR AMINO ACID SEQUENCES		
The electronic data carrier is attached The declaration that the sequence list on paper carrier agrees with the electronic data carrier is attached.		<input type="checkbox"/> <input type="checkbox"/>
If you have used the "Continuation" form, indicate the number of pages attached		
11 SIGNATURE OF THE APPLICANT OR OF THE AUTHORISED AGENT (Name and position of signatory) [signature] Catherine KUEHM-CAUBERE, Patent Engineer		STAMP OF THE PREFECTURE OR OF THE INPI [signature]

First filing

INPI

NATIONAL
INSTITUTE FOR
INDUSTRIAL PROPERTY

**PATENT OF INVENTION
UTILITY CERTIFICATE**
Intellectual Property Code - Book VI

cerfa
No. 11354*04

REQUEST FOR GRANT

Continuation Page No. 1/1

PA/Continuation

Reserved for INPI

DEPOSITION OF DOCUMENTS

DATE **31 MARCH 2004**
PLACE **75 INPI PARIS 26Bis SP**
NATIONAL REGISTRATION NO.
GIVEN BY THE INPI **0403359**

This form is to be completed legibly in black ink

DB 829 @ W / 210103

Your references for this file (optional)

71084-OX

**4 DECLARATION OF PRIORITY OR
REQUEST FOR THE BENEFIT OF THE
FILING DATE OF A PRIOR FRENCH
APPLICATION**

Country or organisation

Date | | | | | | | | | |

No.

Country or organisation

Date | | | | | | | | | |

No.

Country or organisation

Date | | | | | | | | | |

No.

5 APPLICANT (Mark one of the 2 boxes)

☒ Legal person ☐ Natural person

Surname or company name

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE (CNRS)

Forenames

Legal nature

SIREN No.

| | | | | | | | | |

APE-NAF Code

| | | | |

Domicile

Street

3, rue Michel-Ange

or

Postal code and town

| 7 | 5 | 7 | 9 | 4 | PARIS Cedex 16

registered office

Country

FRANCE

Nationality

FRENCH

Telephone no. (optional)

Facsimile no. (optional)

E-mail address (optional)

5 APPLICANT (Mark one of the 2 boxes)

☐ Legal person ☐ Natural person

Surname or company name

Forenames

Legal nature

SIREN No.

| | | | | | | | | |

APE-NAF Code

| | | | |

Domicile

Street

or

Postal code and town

| | | | | |

registered office

Country

Nationality

Telephone no. (optional)

Facsimile no. (optional)

E-mail address (optional)

**11 SIGNATURE OF THE APPLICANT OR
OF THE AUTHORISED AGENT**

(Name and position of signatory) [signature

Catherine KUEHM-CAUBERE,
Patent Engineer

**STAMP OF THE PREFECTURE
OR OF THE INPI**

[signature]

The present invention relates to a new association between a heterocyclic compound and an antioxidant agent for obtaining pharmaceutical compositions for use in the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25.

5 Obesity is a major public health problem in all developed countries. It is also increasing steadily in developing countries and is affecting an ever younger population. Obesity is a well-established risk factor for cardiovascular diseases and is associated with a significantly increased risk of cerebro-vascular accidents, non-insulin-dependent diabetes, vesicular calculi, respiratory dysfunction, osteoarthritis, several forms of cancer and
10 premature death.

It has been found that, in obese people, the generation of reactive oxygenated species released by monocytes and leukocytes is greatly increased with respect to non-obese subjects (J. Clin. Endocrinol. Metab., 2001, 86, 355-362). Elevated plasma concentrations of alpha tumour necrosis factor (TNF α) in obese people stimulate inflammatory processes
15 (J. Clin. Endocrinol. Metab., 1998, 83, 2907-2910) and are responsible for the generation of reactive oxygenated species by leukocytes (Oncogene, 1998, 17, 1639-1651).

The pathological state of obesity is also associated with increased oxidation of lipids and proteins, which may be the cause of high plasma levels of 9- and 13-hydroxy-octadecadienoic acids (9-HODE and 13-HODE) (Totowa : Humano. Press., 1998, 147-
20 155), key indices of lipid peroxidation (J. Clin. Endocrinol. Metab., 2001, 86, 355-362). In parallel, the "antioxidant" capabilities of the body are reduced.

In obese subjects, it has been shown that excessive food intake causes major lipid and protein damage. Over-consumption of calories by obese people can cause the formation of free radicals and expose them to significant oxidative lesions which help to maintain the
25 state of obesity.

The specific markers of oxidation are significantly reduced by a 48-hour fast or by calorie restriction accompanying weight loss (J. Clin. Endocrinol. Metab., 2001, 86, 355-362).


A strategy aimed at reducing the "oxidative burden" on the body by favouring the lipid and carbohydrate metabolisms should result in an exacerbation of the effects and, as a consequence, in weight loss in obese or overweight subjects.

The present invention relates more specifically to the association between a compound favouring the lipid and carbohydrate metabolisms of the body and an antioxidant agent.

This association is novel and exhibits pharmacological properties that are entirely surprising in the area of obesity.

More specifically, the invention relates to the association between a compound favouring the lipid and carbohydrate metabolisms which has a heterocyclic structure, and an antioxidant agent.

The heterocyclic compounds favouring the lipid and carbohydrate metabolisms in accordance with the invention are, more specifically, compounds of formula (I) :



wherein :

- X represents an oxygen or sulphur atom, or a group CH_2 or CH^{R^2} (wherein R^2 together with R^2 forms an additional bond),
- R^1 and R^2 , which may be the same or different, each represent a hydrogen atom, a linear or branched $(\text{C}_1\text{-C}_6)$ alkyl group, an aryl group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyl group in which the alkyl moiety is linear or branched, an aryloxy group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyloxy group in which the alkyl moiety is linear or branched, a linear or

branched (C₁-C₆)alkoxy group, a hydroxy group, an amino group, a linear or branched (C₁-C₆)alkylamino group or a di-(C₁-C₆)alkylamino group in which the alkyl moieties are linear or branched,

or R¹ and R² together form an oxo, thioxo or imino group,

it also being possible for R² together with R'² to form an additional bond,

- A represents a (C₁-C₆)alkylene chain in which one CH₂ group may be replaced by a hetero atom selected from oxygen and sulphur or by a group NR_a (wherein R_a represents a hydrogen atom or a linear or branched (C₁-C₆)alkyl group), or by a phenylene or naphthylene group,

- R³ and R⁴, which may be the same or different, each represent a hydrogen or halogen atom or a group R, OR or NRR' (wherein R and R', which may be the same or different, each represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, an aryl group, an aryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, an aryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a (C₃-C₈)cycloalkyl group, a (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, or a linear or branched (C₁-C₆)polyhaloalkyl group),

or R³ and R⁴, together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,


- R⁵ and R⁶, which may be the same or different, represent a group R as defined hereinbefore,
- D represents:

a benzene nucleus, in which case X cannot represent a group $\text{CH}^{\text{R}^{12}}$ as defined hereinbefore,

or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

- B represents a linear or branched (C₁-C₆)alkyl group or a linear or branched (C₂-C₆)-alkenyl group, those groups being substituted :

♦ by a group of formula (II) :




wherein: - R⁷ represents a group $\text{---}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}$, $\text{---}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---NRR}'$,

$\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---R}'$ or $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}'$, wherein Z represents an oxygen or sulphur atom, and R and R' are as defined hereinbefore,

- and R⁸ represents an aryl group, an arylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, a hetero-aryl group, a heteroarylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, CN, tetrazole, ---OR , $\text{---NRR}'$, $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---R}'$ or $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}'$, wherein Z, R and R' are as defined hereinbefore,

♦ or by a group R⁹, wherein R⁹ represents a CN, tetrazole,



wherein Z, R and R' are as defined hereinbefore, n represents 0, 1, 2, 3, 4, 5 or 6, and R¹⁰ and R¹¹, which may be the same or different, each represent a hydrogen

atom or a linear or branched (C₁-C₆)alkyl group, it being understood that R¹⁰ and R¹¹ cannot simultaneously represent a hydrogen atom,

or B represents a group of formula (II) or a group R⁹ as defined hereinbefore,

it being understood that :

5 * aryl means a phenyl, naphthyl or biphenyl group, it being possible for those groups to be partially hydrogenated,

 * heteroaryl means any mono- or bi-cyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated in one of the rings in the case of bicyclic heteroaryls and which contains 1 to 3 hetero atoms selected from oxygen, nitrogen and
10 sulphur,

it being possible for the aryl and heteroaryl groups thereby defined to be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)polyhaloalkyl, linear or branched (C₁-C₆)alkoxy, hydroxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be the same or different, each represent a hydrogen atom, a
15 linear or branched (C₁-C₆)alkyl group, an aryl group or a heteroaryl group), ester, amido, nitro, cyano, and halogen atoms,

their enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

Even more preferably, the heterocyclic compounds of the association according to the
20 invention are:

* methyl 2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoate,

* methyl 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]phenyl}propanoate,

- * methyl 3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-(2,2,2-trifluoroethoxy)propanoate,
- * methyl 3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-(2,2,2-trifluoro-ethoxy)propanoate,
- 5 * 2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid,
- * 2-ethoxy-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid,
- * methyl 3-{4-[2-(6-[(3-chlorophenyl)(methoxyimino)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-ethoxypropanoate,
- 10 * methyl 3-{4-[2-(6-[(3-chlorophenyl)(hydroxyimino)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-ethoxypropanoate,
- * methyl 2-methoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- 15 * methyl 2-[(*tert*-butoxycarbonyl)amino]-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- * methyl 2-[(*tert*-butoxycarbonyl)amino]-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- 20 * methyl 2-[(butoxycarbonyl)amino]-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,

- * methyl 3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-[(phenoxycarbonyl)amino]propanoate,
- * methyl 2-[[(benzyloxy)carbonyl]amino]-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- 5 * methyl 2-[(*tert*-butoxycarbonyl)(methyl)amino]-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- * *N*-(*tert*-butoxycarbonyl)-4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenylalanine,
- * *N*-(*tert*-butoxycarbonyl)-4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenylalanine,
- 10
- * methyl 2-amino-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- * methyl 2-amino-3-{4-[2-(6-[(hydroxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoate,
- 15 * methyl 3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}-2-(methylamino)propanoate,

their enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

Antioxidant agents according to the invention are, more specifically, anti-free radical agents or free-radical trapping agents, antilipoperoxidant agents, chelating agents or agents capable of regenerating endogenous antioxidants such as glutathione, vitamin C or vitamin E, and also addition salts thereof with a pharmaceutically acceptable acid or base.

Amongst the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, oxalic acid, methanesulphonic acid, camphoric acid, etc..

Amongst the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, *tert*-butylamine, etc..

The antioxidant agent of the association according to the invention is more preferably represented by quinone compounds such as ubiquinone or coenzyme Q₁₀, which acts as a free-radical trapping agent but which is also capable of regenerating vitamin E.

The association to which preference is given in accordance with the invention is 2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]-phenyl}propanoic acid and coenzyme Q₁₀.

Furthermore, the association according to the invention between a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent has entirely surprising pharmacological properties: the Applicant has discovered that a synergy exists between the two compounds of the association allowing a very significant reduction in body fat to be obtained, making it of use in the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25.

In the United States, obesity affects 20 % of men and 25 % of women. Patients having a body mass index ($BMI = \text{weight (kg)} / \text{height}^2 \text{ (m}^2\text{)}$) greater than or equal to 30 are considered to be obese (Int. J. Obes., 1998, 22, 39-47; Obesity Lancet, 1997, 350, 423-426). Obesity ($BMI \geq 30$) and overweight ($25 < BMI < 30$) can have various origins : they may come about following deregulation of food intake, following hormonal disturbance, or following administration of a treatment : treating type II diabetes with sulphonylureas causes patients to gain weight. Similarly, in type I (insulin-dependent) diabetes, insulin therapy is also a cause of weight gain in patients (In Progress in Obesity Research, 8th

International Congress on Obesity, 1999, 739-746 ; Annals of Internal Medicine, 1998, 128, 165-175).

Obesity and overweight are well-established risk factors for cardiovascular diseases: they are associated with a significant increase in the risk of cerebro-vascular accidents and non-insulin-dependent diabetes, because they predispose to insulin-resistance, dyslipidaemia and the appearance of macrovascular disorders (nephropathy, retinopathy, angiopathy).

Further pathologies are the consequence of obesity or overweight: there may be mentioned, in particular, vesicular calculi, respiratory dysfunction, several forms of cancer and, in the case of very severe obesity, premature death (N. Engl. J. Med., 1995, 333, 677-385; JAMA, 1993, 270, 2207-2212).

The association according to the invention allows a weight loss to be obtained which, even if moderate, significantly reduces all the risk factors associated with obesity (Int. J. Obes., 1997, 21, 55-9; Int. J. Obes., 1992, 21, S5-9).

The association according to the invention will therefore be found to be useful in the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25.

The invention accordingly relates to the use of the association between a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25 and less than 30.

In particular, the association according to the invention is of use in the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, such as treatment for type I or II diabetes.

The invention accordingly relates to the use of the association between a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity and of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, such as treatment for type I or II diabetes.

The invention relates also to pharmaceutical compositions comprising the association between a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent, as defined hereinbefore, in combination with one or more pharmaceutically acceptable excipients.

5 Among the pharmaceutical compositions according to the invention, there may be mentioned, more especially, those that are suitable for oral, parenteral or nasal administration, tablets or dragées, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, etc..

10 In particular, the invention relates to pharmaceutical compositions comprising a compound of formula (I) as defined hereinbefore and an antioxidant agent such as coenzyme Q₁₀ or vitamin E, in combination with one or more pharmaceutically acceptable excipients.

The dosage used varies according to the sex, age and weight of the patient, the administration route, the nature of the therapeutic indication or of any associated treatments and ranges from 0.1 mg to 1 g of each component of the association per 15 24 hours in one or more administrations.

The following Examples illustrate the invention but do not limit it in any way.

EXAMPLE A : Change in body weight

Male C57 Black 6 ob/ob mice from 8 to 12 weeks old were used. After being placed in quarantine for one week, they were weighed and then randomised as a function of their 20 weight and 6 homogeneous groups (starting weights not significantly different) were formed. After being weighed, the various compounds under test were injected by the intraperitoneal route once a day for 7 days. The compounds were injected in a solution of DMSO 5 % / Solutol 15 % / qsp H₂O heated at 65°C to ensure good dissolution. In addition, the solution was pre-heated before injection. The mice were weighed every day 25 and the weight obtained after 7 days of treatment was recorded.

The results obtained with the association according to the invention show :

- that the association enables the weight of obese mice to be reduced significantly,

- that there exists a synergy between the 2 components of the association, the weight loss found being much greater in the case of the association than in the case of each component administered on its own.

EXAMPLE B : Pharmaceutical composition


5 100 tablets each containing 30 mg of 2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)-methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid and 10 mg of coenzyme Q₁₀

	2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-1,3-benzo-	
	thiazol-3(2 <i>H</i>)-yl)ethoxy]phenyl}propanoic acid.....	3 g
10	coenzyme Q ₁₀	1 g
	wheat starch.....	20 g
	maize starch.....	20 g
	lactose.....	30 g
	magnesium stearate	2 g
15	silica	1 g
	hydroxypropylcellulose.....	2 g

CLAIMS

1. Association comprising a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent.

2. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is a compound of formula (I) :



wherein :

- X represents an oxygen or sulphur atom, or a group CH_2 or CH^{R^2} (wherein R^2 together with R^2 forms an additional bond),
- R^1 and R^2 , which may be the same or different, each represent a hydrogen atom, a linear or branched $(\text{C}_1\text{-C}_6)$ alkyl group, an aryl group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyl group in which the alkyl moiety is linear or branched, an aryloxy group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyloxy group in which the alkyl moiety is linear or branched, a linear or branched $(\text{C}_1\text{-C}_6)$ alkoxy group, a hydroxy group, an amino group, a linear or branched $(\text{C}_1\text{-C}_6)$ alkylamino group or a di- $(\text{C}_1\text{-C}_6)$ alkylamino group in which the alkyl moieties are linear or branched,
or R^1 and R^2 together form an oxo, thioxo or imino group,
it also being possible for R^2 together with R^2 to form an additional bond,
- A represents a $(\text{C}_1\text{-C}_6)$ alkylene chain in which one CH_2 group may be replaced by a hetero atom selected from oxygen and sulphur or by a group NR_a (wherein R_a

represents a hydrogen atom or a linear or branched (C₁-C₆)alkyl group), or by a phenylene or naphthylene group,


- R³ and R⁴, which may be the same or different, each represent a hydrogen or halogen atom or a group R, OR or NRR' (wherein R and R', which may be the same or different, each represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, a linear or branched (C₂-C₆)alkenyl group, a linear or branched (C₂-C₆)alkynyl group, an aryl group, an aryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, an aryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, an aryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a heteroaryl group, a heteroaryl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkenyl group in which the alkenyl moiety is linear or branched, a heteroaryl-(C₂-C₆)alkynyl group in which the alkynyl moiety is linear or branched, a (C₃-C₈)cycloalkyl group, a (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl group in which the alkyl moiety is linear or branched, or a linear or branched (C₁-C₆)polyhaloalkyl group),
 or R³ and R⁴, together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,

- R⁵ and R⁶, which may be the same or different, represent a group R as defined hereinbefore,
- D represents:

a benzene nucleus, in which case X cannot represent a group $\begin{array}{c} \text{R}^2 \\ | \\ \text{CH} \end{array}$ as defined hereinbefore,

or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,

- B represents a linear or branched (C₁-C₆)alkyl group or a linear or branched (C₂-C₆)-alkenyl group, those groups being substituted :
 ♦ by a group of formula (II) :




wherein: - R⁷ represents a group $\text{---}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}$, $\text{---}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---NRR}'$,

$\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---R}'$ or $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}'$, wherein Z represents an oxygen or sulphur atom, and R and R' are as defined hereinbefore,

- and R⁸ represents an aryl group, an arylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, a hetero-aryl group, a heteroarylalkyl group wherein the alkyl moiety contains from 1 to 6 carbon atoms and may be linear or branched, CN, tetrazole, ---OR , $\text{---NRR}'$, $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---R}'$ or $\text{---N(R)}\overset{\text{Z}}{\underset{\parallel}{\text{C}}}\text{---OR}'$, wherein Z, R and R' are as defined hereinbefore,

♦ or by a group R⁹, wherein R⁹ represents a CN, tetrazole,



wherein Z, R and R' are as defined hereinbefore, n represents 0, 1, 2, 3, 4, 5 or 6, and R¹⁰ and R¹¹, which may be the same or different, each represent a hydrogen atom or a linear or branched (C₁-C₆)alkyl group, it being understood that R¹⁰ and R¹¹ cannot simultaneously represent a hydrogen atom,

or B represents a group of formula (II) or a group R⁹ as defined hereinbefore,

it being understood that :

* aryl means a phenyl, naphthyl or biphenyl group, it being possible for those groups to be partially hydrogenated,

* heteroaryl means any mono- or bi-cyclic aromatic group containing 5 to 10 members, which may be partially hydrogenated in one of the rings in the case of bicyclic heteroaryls and which contains 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

5 it being possible for the aryl and heteroaryl groups thereby defined to be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)polyhaloalkyl, linear or branched (C₁-C₆)alkoxy, hydroxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be the same or different, each represent a hydrogen atom, a linear or branched (C₁-C₆)alkyl group, an aryl group or a heteroaryl group), ester, amido,
10 nitro, cyano, and halogen atoms,

an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

3. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is 2-ethoxy-3-{4-[2-(6-[(methoxyimino)(phenyl)methyl]-2-oxo-
15 1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid, an enantiomer or diastereoisomer thereof, or an addition salt thereof with a pharmaceutically acceptable acid or base.

4. Association according to claim 1, wherein the antioxidant agent is coenzyme Q₁₀.

5. Association according to claim 1, wherein the antioxidant agent is vitamin E.

6. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(methoxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid and
20 coenzyme Q₁₀.

7. Association according to claim 1, which is 2-ethoxy-3-{4-[2-(6-[(methoxyimino)-(phenyl)methyl]-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]phenyl}propanoic acid and vitamin E.

8. Pharmaceutical compositions comprising as active ingredient a compound favouring the lipid and carbohydrate metabolisms in association with an antioxidant agent according to one of claims 1 to 7, on their own or in combination with one or more pharmaceutically acceptable excipients.

5 9. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.

10. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

10 11. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

12. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

15 13. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

20 14. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

15. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

16. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.

Received on 28/04/04

INPI

NATIONAL
INSTITUTE FOR
INDUSTRIAL PROPERTY

**PATENT OF INVENTION
UTILITY CERTIFICATE**
Intellectual Property Code - Book VI

cerfa
No. 11235*02

PATENTS DIVISION

26bis, rue de Saint Pétersbourg
75800 Paris Cedex 08
Telephone: 01 53 04 53 04
Facsimile: 01 42 93 59 30

DECLARATION OF INVENTORSHIP

Page No. 1 / 2

(if the Applicant is not the inventor or not the only inventor)

This form is to be completed legibly in black ink DB 113 W /260899

Your references for this file (optional)		71084-OX	
NATIONAL REGISTRATION NO.		0403359	
TITLE OF THE INVENTION (maximum 200 characters or spaces) NEW ASSOCIATION BETWEEN A HETEROCYCLIC COMPOUND AND AN ANTIOXIDANT AGENT, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM			
APPLICANT(S): LES LABORATOIRES SERVIER 12, Place de la Défense 92415 COURBEVOIE Cedex FRANCE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 3, rue Michel Ange 75794 PARIS Cedex FRANCE			
DESIGNATE(S) AS INVENTOR(S) : (Indicate at the top right-hand side "Page No. 1/1". If there are more than three inventors, use an identical form and number each page indicating the total number of pages).			
Surname		CASTEILLA	
Forenames		Louis	
Address	Street	46, avenue des Troubadours	
	Postal code and town	31750	ESCALQUENS
Belonging company (optional)			
Surname		PENICAUD	
Forenames		Luc	
Address	Street	32, rue de Puymaurin	
	Postal code and town	31400	TOULOUSE
Belonging company (optional)			
Surname		BERTHELOT	
Forenames		Pascal	
Address	Street	12, Mail du Bon Pêcheur	
	Postal code and town	59320	HAUBOURDIN
Belonging company (optional)			
DATE AND SIGNATURE(S) OF THE APPLICANT(S) OR OF THE AUTHORISED AGENT (Name and position of signatory) Catherine KUEHM-CAUBERE, Patent Engineer		[signature]	

Law No. 78-17 of 6 January 1978 relating to information processing, data files and rights applies to the responses made on this form. It guarantees right of access to and correction of the data concerning you at the INPI.

Received on 28/04/04

INPI

NATIONAL
INSTITUTE FOR
INDUSTRIAL PROPERTY

**PATENT OF INVENTION
UTILITY CERTIFICATE**
Intellectual Property Code - Book VI

cerfa
No. 11235*02

PATENTS DIVISION
26bis, rue de Saint Pétersbourg
75800 Paris Cedex 08
Telephone: 01 53 04 53 04
Facsimile: 01 42 93 59 30

DECLARATION OF INVENTORSHIP
Page No. 2 / 2
(if the Applicant is not the inventor or not the only inventor)

This form is to be completed legibly in black ink DB 113 W /260899

Your references for this file (<i>optional</i>)		71084-OX	
NATIONAL REGISTRATION NO.		0403359	
TITLE OF THE INVENTION (maximum 200 characters or spaces) NEW ASSOCIATION BETWEEN A HETEROCYCLIC COMPOUND AND AN ANTIOXIDANT AGENT, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM			
APPLICANT(S): LES LABORATOIRES SERVIER 12, Place de la Défense 92415 COURBEVOIE Cedex FRANCE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 3, rue Michel Ange 75794 PARIS Cedex FRANCE			
DESIGNATE(S) AS INVENTOR(S) : (Indicate at the top right-hand side "Page No. 1/1". If there are more than three inventors, use an identical form and number each page indicating the total number of pages).			
Surname		DACQUET	
Forenames		Catherine	
Address	Street	5, rue des Dardanelles	
	Postal code and town	75017	PARIS
Belonging company (<i>optional</i>)			
Surname		CAIGNARD	
Forenames		Daniel-Henri	
Address	Street	22, avenue de la République	
	Postal code and town	78230	LE PECQ
Belonging company (<i>optional</i>)			
Surname			
Forenames			
Address	Street		
	Postal code and town		
Belonging company (<i>optional</i>)			
DATE AND SIGNATURE(S) OF THE APPLICANT(S) OR OF THE AUTHORISED AGENT (Name and position of signatory) Catherine KUEHM-CAUBERE, Patent Engineer		[signature]	

Law No. 78-17 of 6 January 1978 relating to information processing, data files and rights applies to the responses made on this form. It guarantees right of access to and correction of the data concerning you at the INPI.